News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Staff September 11, 2023 Iframe sync Post navigation Previous: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext: Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors More Stories Brain Mental Health News Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant Staff December 22, 2025 Antimicrobial News Nutrition Pharmaceutical Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin Staff December 22, 2025 News Pharmaceutical CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities Staff December 22, 2025
